Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir

Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis. We encountered a patient exhibiting severe hyperbilirubine...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Hayato, Tajiri, Kazuto, Nagata, Kohei, Kawai, Kengo, Minemura, Masami, Sugiyama, Toshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965544/
https://www.ncbi.nlm.nih.gov/pubmed/27504082
http://dx.doi.org/10.1159/000447486
_version_ 1782445274873987072
author Baba, Hayato
Tajiri, Kazuto
Nagata, Kohei
Kawai, Kengo
Minemura, Masami
Sugiyama, Toshiro
author_facet Baba, Hayato
Tajiri, Kazuto
Nagata, Kohei
Kawai, Kengo
Minemura, Masami
Sugiyama, Toshiro
author_sort Baba, Hayato
collection PubMed
description Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis. We encountered a patient exhibiting severe hyperbilirubinemia during combined therapy, which is an unreported side effect of DCV and ASV. A 78-year-old woman with cirrhosis developed hyperbilirubinemia >10 mg/dl without transaminitis 3 weeks after starting combined therapy. We suspected DAAs-induced liver disorder and discontinued treatment, which resulted in the improvement of hyperbilirubinemia. Caution is required in the use of DAAs for patients with advanced cirrhosis.
format Online
Article
Text
id pubmed-4965544
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-49655442016-08-08 Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir Baba, Hayato Tajiri, Kazuto Nagata, Kohei Kawai, Kengo Minemura, Masami Sugiyama, Toshiro Case Rep Gastroenterol Single Case Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis. We encountered a patient exhibiting severe hyperbilirubinemia during combined therapy, which is an unreported side effect of DCV and ASV. A 78-year-old woman with cirrhosis developed hyperbilirubinemia >10 mg/dl without transaminitis 3 weeks after starting combined therapy. We suspected DAAs-induced liver disorder and discontinued treatment, which resulted in the improvement of hyperbilirubinemia. Caution is required in the use of DAAs for patients with advanced cirrhosis. S. Karger AG 2016-07-08 /pmc/articles/PMC4965544/ /pubmed/27504082 http://dx.doi.org/10.1159/000447486 Text en Copyright © 2016 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Baba, Hayato
Tajiri, Kazuto
Nagata, Kohei
Kawai, Kengo
Minemura, Masami
Sugiyama, Toshiro
Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
title Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
title_full Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
title_fullStr Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
title_full_unstemmed Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
title_short Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
title_sort hyperbilirubinemia without transaminitis during combined therapy with daclatasvir and asunaprevir
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965544/
https://www.ncbi.nlm.nih.gov/pubmed/27504082
http://dx.doi.org/10.1159/000447486
work_keys_str_mv AT babahayato hyperbilirubinemiawithouttransaminitisduringcombinedtherapywithdaclatasvirandasunaprevir
AT tajirikazuto hyperbilirubinemiawithouttransaminitisduringcombinedtherapywithdaclatasvirandasunaprevir
AT nagatakohei hyperbilirubinemiawithouttransaminitisduringcombinedtherapywithdaclatasvirandasunaprevir
AT kawaikengo hyperbilirubinemiawithouttransaminitisduringcombinedtherapywithdaclatasvirandasunaprevir
AT minemuramasami hyperbilirubinemiawithouttransaminitisduringcombinedtherapywithdaclatasvirandasunaprevir
AT sugiyamatoshiro hyperbilirubinemiawithouttransaminitisduringcombinedtherapywithdaclatasvirandasunaprevir

Ejemplares similares